Abhay Bangi – Partner, Life Sciences & Healthcare Lead ASEAN, EY

EY’s Abhay Bangi highlights the key trends across the ASEAN life sciences space, how the COVID-19 pandemic has accelerated them, and charts Singapore’s course towards becoming a world-class biotech investment destination.  
Value-Based healthcare in this part of the world will be implemented in different ways. It will come less through contracts, but more through pricing regulations
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report